Jazz Pharmaceuticals Reports Positive Phase 3 Results for Zepzelca® Combined with Atezolizumab in Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinected...

October 16, 2024 | Wednesday | News
Amgen Announces Positive Phase 3 Results for UPLIZNA® in Generalized Myasthenia Gravis, Paving the Way for New Treatment Options

Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...

October 16, 2024 | Wednesday | News
Biofrontera Completes Treatment Phase in First U.S. Phase 3 PDT Study for sBCC, Data Analysis Underway

First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...

October 15, 2024 | Tuesday | News
Eli Lilly's Mirikizumab Shows Promising Histologic Response in Phase 3 Study for Crohn's Disease, Outperforming Ustekinumab

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...

October 15, 2024 | Tuesday | News
Exelixis and MSD Announce Strategic Collaboration to Evaluate Zanzalintinib in Combination with KEYTRUDA® and WELIREG® for Advanced Cancers

Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the companies have entered i...

October 15, 2024 | Tuesday | News
Dizal Secures Breakthrough Therapy Designation for Sunvozertinib in Advanced NSCLC Treatment

Dizal (, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that th...

October 14, 2024 | Monday | News
Aileron Therapeutics Showcases Promising LTI-03 Results for Idiopathic Pulmonary Fibrosis at ICLAF

Aileron Therapeutics,  a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...

October 14, 2024 | Monday | News
Pfizer Receives FDA Approval for HYMPAVZI™: A New Treatment for Hemophilia A and B

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis ...

October 14, 2024 | Monday | News
Burning Rock and Dizal Announce First NGS-Based Lung Cancer Diagnostic Approval by China’s NMPA

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision onco...

October 11, 2024 | Friday | News
RoukenBio Launches New Brand Identity and Completes Phase 2 Expansion of Discovery Centre in Scotland

  RoukenBio, the Collaborative Research Organisation (CRO) formerly known as Antibody Analytics, has today announced completion of the phase 2 expans...

October 04, 2024 | Friday | News
Oncocyte's GraftAssure™ Assay Adopted by Top U.S. and German Transplant Hospitals, Progresses Toward FDA Submission

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume Company clears first stage...

October 03, 2024 | Thursday | News
Citryll Launches Pioneering Collaboration with Dutch Rheumatology Experts to Advance NET-Targeting Therapies for Rheumatoid Arthritis

Learnings will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013 ...

October 03, 2024 | Thursday | News
Kailera Therapeutics Launches with Ambitious Plans for GLP-1 Drugs Targeting Obesity and Metabolic Conditions

In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...

October 02, 2024 | Wednesday | News
LeaderMed and Combiphar Form Joint Venture to Launch Phase 3 Trial of Novel Diabetes Treatment in Indonesia

LeaderMed Group (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast Asia, ann...

October 01, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close